Start here: real clots, contested meaning, risky treatment
Three things need separating. Abnormal microclots can be detected in the plasma of some people with long COVID, which is a real laboratory finding. Whether they cause the illness is genuinely contested. And the intensive blood-thinning regimens marketed on the back of them are unproven and carry serious bleeding risk.
This page holds all three at once. The honest position is interest in the science paired with strong caution about the treatment, because this is an area where a plausible idea has run ahead of the evidence into risky practice.
microclots measurable in PASC plasmacausal role and methods debateddrives unproven triple-anticoagulation
What microclots are
The proposing researchers describe an abnormal, amyloid form of fibrin, the protein that makes clots, that is unusually resistant to the body's normal clot-dissolving machinery. These deposits can be stained and seen under a fluorescence microscope in platelet-poor plasma, and they trap other inflammatory proteins.
The hypothesis is that these persistent microclots block the smallest capillaries, limiting the passage of red blood cells and therefore oxygen delivery to tissues. That would offer a single explanation for fatigue, brain fog, and exertional symptoms, which is part of the idea's appeal. A single, visible, treatable cause is more satisfying than a scatter of mechanisms, and that very neatness is one reason the hypothesis spread faster than the evidence behind it.
What the evidence shows
Studies from the proposing group report fibrinolysis-resistant microclots and raised levels of clot-stabilising proteins such as antiplasmin in long COVID plasma, distinguishing it from healthy controls. The laboratory observation of abnormal clotting material is repeatable in their hands.
What is far less settled is the leap from that observation to causation and treatment. Independent replication has been mixed, the staining and counting methods are debated, and the link between microclot burden and specific symptoms is not established. Real finding, contested interpretation, and that gap is exactly where the marketed treatment becomes a problem.
largely from proponent groups; independent replication mixed
Why the treatment is the danger
The microclot hypothesis has spawned a promoted treatment: a triple regimen of two antiplatelet drugs and an anticoagulant, sometimes given through private clinics. The supporting evidence is a small, unblinded case series, not a controlled trial, and the approach carries a real risk of serious bleeding.
This is the heart of the caution. Even if microclots matter, that would not make an unproven, bleeding-risk regimen safe or effective. Major trials of anticoagulation for long COVID have generally disappointed, which further undercuts the rush to thin the blood aggressively.
triple anticoagulation: serious bleeding risk, no controlled-trial support
How to weigh it
The fair summary is that the microclot finding is a serious scientific hypothesis under active investigation, and the treatment built on it is not ready and not safe to pursue outside a trial. Those two judgments can and should be held together.
Proper randomised trials of clot-targeting approaches, with bleeding monitored, are what would settle whether this helps. Until they report, the evidence supports curiosity about the biology and refusal of the marketed protocol.
How to read claims about it
If a clinic offers a microclot test followed by triple blood thinners, the questions to ask are whether the test is validated, whether a controlled trial shows the treatment helps, and how the bleeding risk is managed. For now the answers are no, no, and not adequately.
Compare any microclot offering against that standard. The science deserves attention and the commercial treatment deserves refusal, and recognising the difference is what protects you from a real and avoidable harm.
What we don't know
Honest about the edges of the evidence. These are open questions, not settled answers.
- Whether microclots cause long COVID symptoms or are a downstream marker.
- Whether independent labs reliably reproduce the microclot findings and methods.
- Whether any clot-targeting treatment improves symptoms in a controlled trial.
- How microclot burden relates to specific symptoms and to oxygen delivery.
- How microclots connect to inflammation, barrier leak, and viral persistence.
- How to weigh any benefit against the bleeding risk of aggressive anticoagulation.
What this means for you
Microclots are a real laboratory finding in some people with long COVID and a serious hypothesis worth testing. It is reasonable to find the science interesting and to want it investigated properly.
It is not a reason to pursue the promoted triple blood-thinning treatment, which is unproven and carries serious bleeding risk. Be very cautious about clinics that sell a microclot test and aggressive anticoagulation; wait for controlled trials.
References
Each reference links to the source on PubMed, PMC, or the publisher.